Last reviewed · How we verify
NAVX-010
At a glance
| Generic name | NAVX-010 |
|---|---|
| Also known as | Gonyautoxin 2/3 |
| Sponsor | Algenis SpA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study (PHASE1, PHASE2)
- NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |